Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Erin Singh"'
Autor:
Joshua Richter, Peggy L. Lin, Viviana Garcia‐Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8005-8017 (2023)
Abstract Backgound Lenalidomide‐based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of head‐to‐head comparison, matc
Externí odkaz:
https://doaj.org/article/25757ea5c0d04b968bda33b211f19236
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-3 (2021)
Externí odkaz:
https://doaj.org/article/9cdbae7dfa6b4480a001ade08c52f08b
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-3 (2021)
Blood Cancer Journal
Blood Cancer Journal
Background Multiple myeloma (MM) is the second most common hematologic malignancy and is associated with significant patient burden. Renal impairment has been shown to affect up to 50% of patients (pts) with MM. Renal impairment is an independent pre
Autor:
Joshua Richter, Peggy Lin, Patricia Guyot, Zheng-Yi Zhou, Viviana Garcia-Horton, Mark Sievert, Erin Singh
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S156-S157
Background The phase 3 IKEMA trial evaluated isatuximab plus carfilzomib and dexamethasone (IsaKd) for relapsed multiple myeloma after 1–3 therapy lines. As no head-to-head comparison exists, we compared IsaKd vs daratumumab plus lenalidomide and d
Publikováno v:
Blood. 138:4114-4114
Introduction: Despite numerous therapies approved for multiple myeloma (MM) in the past decade, the disease remains largely incurable. As a result, patients (pts) typically require successive lines of therapy, comprised of various combinations of dru
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S297
Context: High-risk cytogenetic features in patients with multiple myeloma (MM) have been linked to poorer prognosis. Improved outcomes for these patients remain a high unmet medical need. Objective: To assess high-risk cytogenetic testing and to desc